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Abstract
Pathogens have evolved sophisticated mechanisms to evade detection and destruction by the host immune system. Large
DNA viruses encode homologues of chemokines and their receptors, as well as chemokine-binding proteins (CKBPs) to
modulate the chemokine network in host response. The SECRET domain (smallpox virus-encoded chemokine receptor)
represents a new family of viral CKBPs that binds a subset of chemokines from different classes to inhibit their activities,
either independently or fused with viral tumor necrosis factor receptors (vTNFRs). Here we present the crystal structures of
the SECRET domain of vTNFR CrmD encoded by ectromelia virus and its complex with chemokine CX3CL1. The SECRET
domain adopts a b-sandwich fold and utilizes its b-sheet I surface to interact with CX3CL1, representing a new chemokine-
binding manner of viral CKBPs. Structure-based mutagenesis and biochemical analysis identified important basic residues in
the 40s loop of CX3CL1 for the interaction. Mutation of corresponding acidic residues in the SECRET domain also affected
the binding for other chemokines, indicating that the SECRET domain binds different chemokines in a similar manner. We
further showed that heparin inhibited the binding of CX3CL1 by the SECRET domain and the SECRET domain inhibited
RAW264.7 cell migration induced by CX3CL1. These results together shed light on the structural basis for the SECRET
domain to inhibit chemokine activities by interfering with both chemokine-GAG and chemokine-receptor interactions.
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Introduction
Chemokines orchestrate leukocyte migration during immune
surveillance, inflammation, and development [1,2,3,4]. They
comprise a large family (,50) of small proteins (,7–14 KD) that
are classified into four classes (C, CC, CXC, and CX3C, where X
is any residue) based on the spacing of conserved cysteine residues
at the N-terminus [5]. The CC and CXC classes are by far the
largest groups of chemokines, whereas the C class consists of two
members (XCL1 and XCL2) and the CX3C class contains only
one member (CX3CL1). All chemokines share a remarkably
similar structural fold, consisting of an extended N-terminus, an
antiparallel three-stranded b-sheet and a C-terminal helix [6].
Chemokines exert their biological activities through binding with
their cognate G protein-coupled receptors expressed on the surface
of leukocytes, as well as binding with endothelial or matrix
glycosaminoglycans (GAGs) to form chemokine gradients along
which cells travel across endothelium and into tissues [6]. The
molecular basis of chemokine-GAG and chemokine-receptor
interactions has not been well understood [6,7]. It has been
suggested that the basic residues (typically Arg and Lys) involved in
GAG interaction are more or less scattered along the polypeptide
chain and form four distinct clusters on the surface of chemokines
[8], while the N-termini of all studied chemokines is critical for
inducing signaling by their respective receptors [6].
The chemokine network is an important component of host
immune response to viral infection [1,3], which is also extensively
modulated by viruses especially large DNA viruses to evade host
reactions. Poxviruses and herpesviruses encode their own
chemokines, chemokine receptors and chemokine-binding pro-
teins (CKBPs) [9,10,11]. The viral CKBPs identified so far are
unrelated to any host proteins and exhibit diverse chemokine-
binding profiles, reflecting differences in viral tropism and
pathogenesis. The viral CC chemokine inhibitor (vCCI, also
called T1/35 kDa) secreted by several poxviruses including
cowpox virus (CPXV), ectromelia virus (ECTV) and vaccinia
virus (VACV) is the most extensively studied, which binds many
CC chemokines but not C, CXC, and CX3C chemokines to block
chemokine-receptor interaction [12,13,14,15,16]. The VACV
A41 and ECTV E163, representative members of another family
of poxviral CKBPs, interact with a subset of CC and CXC
chemokines to block chemokine-GAG interaction [17,18]. Mouse
c-herpesvirus 68 encodes a unique CKBP named as the M3
protein that is able to bind chemokines from the C, CC, CXC,
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revealed that M3 disrupts both chemokine-receptor and chemo-
kine-GAG interactions [21,22,23]. Other viral CKBPs, such as M-
T7 from myxoma virus (MYXV), a CKBP from orf virus (ORFV),
p21.5 from human cytomegalovirus and glycoprotein G from a-
herpesviruses, have also been described previously [24,25,26,27].
Four different genes encoding viral tumor necrosis factor
receptors (vTNFRs) have been identified in poxviruses, consisting
of cytokine response modifier B (CrmB), CrmC, CrmD, and CrmE
[10]. They contribute to pathogenesis of poxviruses and reflect the
complex regulation of TNF-mediated host immune response [28].
In addition to the anti-TNF activity attributed to the N-terminal
four cysteine-rich domains (CRDs) homologous to host TNF
receptors [29], CrmB and CrmD have anti-chemokine activity
attributed to a unique C-terminal extension (,160 aa), named as
the SECRET domain(smallpox virus-encoded chemokine receptor)
[30].BiochemicalanalysisrevealedthattheSECRETdomainbinds
a subset of human and mouse CC, CXC and C chemokines,
including CCL28, CCL25, CCL20, CXCL12, CXCL13,
CXCL14, and XCL1 [30]. The identification of other poxvirus
genes encoding homologues with the SECRET domain indicates
that the SECRET domain represents a new family of viral CKBPs,
which has specific folding to allow its binding with chemokines,
eitherindependently orfusedwithvTNFRs[30,31]. A recent report
predicted the structural homology of the SECRET domain with
CPXV vCCI and VACV A41 and also analyzed its structural
differences from vCCI and A41 based on a de novo model [32]. Here
we report the crystal structures of the SECRET domain of CrmD
encoded by an ECTV strain [33] and the complex of it with
chemokine CX3CL1. These structures, together with biochemical
and chemotaxis assays, reveal the structural basis for the SECRET
domain to bind chemokines and also shed light on its anti-
chemokine structural mechanisms.
Results
Structure of the SECRET domain
The crystal structure of the SECRET domain (residues
S1622D320) was determined at a resolution of 1.57 A ˚ by using
single-wavelength anomalous dispersion (SAD) method with a Br-
soaked derivative (Table 1 and Figure S1 in Text S1). There are
two SECRET domains (molecules A and B) in the asymmetric unit
(Figure 1A), related by a non-symmetrical two-fold axis with an
r.m.s.d. of 0.62 A ˚ for all Ca atoms. Although these two monomers
bind each other tightly with a buried surface of ,1160 A ˚ 2, the size
exclusion chromatography revealed that it is monomeric in
solution (Figure S2 in Text S1). The same phenomenon was also
observed in the CPXV and ECTV vCCI crystal structures
[34,35]. Therefore, the SECRET dimer in the asymmetric unit is
caused by molecular packing and unlikely has any functional
significance.
The SECRET domain monomer adopts a b-sandwich fold,
consisting of two parallel b-sheets and the connecting loops
(Figure 1B and Figure S3 in Text S1). The b-sheet I consists of five
anti-parallel strands 1, 5, 6, 10 and 11 (Figure 1B and Figure S3 in
Text S1). The b-sheet II consists of six strands, which can be
further divided into two segments (antiparallel strands 2, 3, 4 and
7; antiparallel strands 8 and 9) (Figure 1B and Figure S3 in Text
S1). The b-sheet II outside surface is completely exposed to solvent
(Figure 1B), whereas the solvent accessibility of b-sheet I outside
surface is limited by a long C-terminal loop after strand 11
surrounding the bottom half of b-sheet I (Figure 1B). A disulfide
bond, C1802C317, further fixes the conformation of this
extended loop by connecting it to the 1–2 loop (Figure 1B and
Figure S3 in Text S1).
Structural comparison with other poxviral CKBPs
The overall b-sandwich topology of the SECRET domain is
similar to that of vCCI and A41 [17,34,35,36]. However, there are
several significant differences in the arrangement of certain
secondary structure elements, making the CrmD SECRET
domain more compact than vCCI and A41 and also directly
affecting its binding with chemokines. In the following comparison
and description, we use the structure of vCCI from ECTV as the
representative member of the vCCI family [35]. The first
difference is at the 7–9 loop (S2482H266) in the SECRET
domain, corresponding to residues S140 to I168 in vCCI and
E113 to M144 in A41 (Figure 2A and Figure S4 in Text S1). The
long S1402I168 loop in vCCI wraps the b-sheet I at the top half,
and the long E1132M144 loop in A41 wraps the whole b-
sandwich from bottom side (Figure 2A). In collaboration with the
conserved C-terminal loop surrounding the bottom half of b-sheet
I, these two long loops further limit the solvent exposable surface
of b-sheet I in vCCI and A41, respectively (Figure 2A). The 7–9
loop in the SECRET domain goes up and down at the b-sheet II
side of the b-sandwich, and residues S252 to Q254 form the strand
8i nb-sheet II (Figure 2A and Figure S4 in Text S1). Therefore, it
does not limit the solvent exposable surface of b-sheet I in the
SECRET domain. The second difference occurs at the 2–3 loop
(I1842S186) in the SECRET domain, whose length is nearly the
same as that in A41 (K392Y40) and much shorter than that in
vCCI (S522P66) (Figure 2A and Figure S4 in Text S1). The third
difference occurs at the 6–7 loop, whose length in the SECRET
domain (N2272C238) is also much shorter than that in vCCI
(S1072C131) and A41 (S802C104) (Figure 2A and Figure S4 in
Text S1). There is an a-helix in this loop region of vCCI and A41,
which is absent in the SECRET domain (Figure 2A).
The electrostatic complementarity plays a critical role in the
binding of chemokines by vCCI and A41 [17,34,35,36]. The b-
sheet II of vCCI exhibits strong electronegative character.
Negative charge patches, including the protruded acidic 2–3 loop
(S522P66) (Figure 3A and Figure S4 in Text S1), are involved in
the interactions with positive charged residues of bound
Author Summary
Chemokines are a family of small proteins that help the
immune system fight against invading pathogens by
inducing the white blood cells to the areas of infection
and inflammation. Due to the important roles of chemo-
kines in immune response, the pathogens evolve diverse
mechanisms to neutralize their activities. One example is
that large DNA viruses, such as poxviruses and herpesvi-
ruses can produce chemokine binding proteins (CKBPs) to
sequester chemokines during the infection. The SECRET
domain represents a new family of viral CKBPs that was
originally identified as a C-terminal extension of the viral
tumor necrosis factor receptors (vTNFRs). We determined
the three-dimensional structures of the SECRET domain
and its complex with chemokine CX3CL1, revealing a new
chemokine-binding manner of viral CKBPs. We also
showed that other chemokines from different classes
may be bound by the SECRET domain in a way similar to
that observed in the SECRET/CX3CL1 complex structure.
Our biochemical and chemotaxis assays also suggest that
the SECRET domain is able to interfere with both
chemokine-GAG and chemokine-receptor interactions,
both of which are essential for chemokine activities in vivo.
Structures of the SECRET Domain with CX3CL1
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complex with chemokine CCL4 [36]. The 2–3 loop (K392Y40) in
A41 is much shorter than that in vCCI, but its b-sheet II also
exhibits negative charge patches (Figure 3B and Figure S4 in Text
S1) and may contribute to the interaction with bound chemokine
[17]. The opposite b-sheet I of vCCI and A41 is comparatively
uncharged and electropositive, respectively (Figure 3A and 3B).
The SECRET domain exhibits different electrostatic surface by
switching the surface charge property as observed in vCCI and
A41. Its b-sheet II has no remarkable electrostatic properties,
while the opposite b-sheet I exhibits strong negative charge in the
solvent exposable region, contributed by acidic residues D167,
E169, D228, D290, D316, and E318 (Figure 3C and Figure S4 in
Text S1). The distinct surface charge property of the SECRET
domain leads us to speculate that it may bind chemokines in a
different manner by using the solvent exposable and negatively
charged surface of b-sheet I.
Structure of the SECRET/CX3CL1 complex
To directly elucidate the chemokine binding by the SECRET
domain, we reconstituted a complex of the SECRET domain with
the chemokine domain of CX3CL1 and determined its structure
at a resolution of 2.6 A ˚. The structure was solved by the molecular
replacement method using the SECRET domain and CX3CL1
structures as search models, and refined to final Rwork and Rfree
factors of 19.6% and 25.0%, respectively (Table 1 and Figure S1
in Text S1).
In the complex, one SECRET domain monomer binds one
CX3CL1 monomer, displaying a 1:1 stoichiometry (Figure 4A).
The chemokine domain of CX3CL1 in the complex adopts the
typical chemokine-fold topology, consisting of an extended N-loop
(C82P20), a short 310 helix (V212L23), a 3-stranded anti-parallel
b-sheet (b1, L242Q29; b2: I392T43; b3: R472A51), a C-
terminal helix (Q562A69) packing against the b-sheet, and the
30s loop (N302A38) and 40s loop (R442H46) connecting the
strands in the b-sheet (Figure 4A). The N-terminal residues Q1 to
K7 and C-terminal residues R74 to G76 are disordered in the
structure. The SECRET domain contacts the CX3CL1 with its b-
sheet I, burying a surface of ,530 A ˚ 2 (Figure 4A). The SECRET
domain contacting residues are from the strands 1, 5, and 6 of b-
sheet I and the C-terminal extended loop, while the CX3CL1
contacting residues are from the N-loop, 310 helix, 40s loop, and
the b3 strand (Figure 4A). The binding interface can be described
as a small hydrophobic core surrounded by a large halo of
hydrophilic interactions. The hydrophobic core is composed of
residues Y212 and F225 from CrmD, and I19, L23 and F49 from
CX3CL1 (Figure 4B). The surrounding hydrophilic interactions
are composed of hydrogen bonds and salt-bridges. There is an
obvious electrostatic complementarity between the SECRET
domain and CX3CL1 at the interface (Figure 4C). The acidic
residues D167, E169, and D316 from the SECRET domain form
Figure 1. Crystal structure of the SECRET domain. (A) Ribbon diagram of two SECRET domain monomers in the asymmetric unit. (B) Ribbon
diagram of the SECRET domain monomer showing the b-sheet I (left) and b-sheet II (right).
doi:10.1371/journal.ppat.1002162.g001
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respectively (Figure 4D).
To further elucidate the roles of important residues in complex
formation, we mutated hydrophobic residues I19A, L23A and
F49A and charged residues K18A, R44A, and R47A in CX3CL1,
and measured the binding affinities of these mutants with the
SECRET domain using surface plasmon resonance (SPR) method.
We performed two independent measurements for each protein
sample and the results are listed in Table 2. The SECRET domain
interacted with CX3CL1 with an affinity of 0.6860.26 mM
(Table 2 and Figure S5 in Text S1) The CXC3L1 mutants
I19A,L23A, and F49A bound the SECRET domain with affinities
of 0.9660.32, 4.4961.13, and 4.2060.45 mM, respectively
(Table 2 and Figure S5 in Text S1). The CX3CL1 mutants
K18A, R44A, and R47A bound the SECRET domain with
affinities of 10.960.6 mM, 16.1560.45 mM, and 36.4561.95 mM,
respectively (Table 2 and Figure S5 in Text S1). All mutations
resulted in the decrease of the binding affinity between the
SECRET domain and CX3CL1. Mutating charged residues K18,
R44, and R47 in CX3CL1 induced more significant binding
affinity decrease than mutating hydrophobic residues I19, L23,
and F49, suggesting the importance of the salt-bridge interactions
in the complex formation of the SECRET domain with CX3CL1.
Comparison with other CKBP/chemokine complexes
The SECRET/CX3CL1 and previous reported vCCI/CCL4
complexes [36] are different in the association manner between
CKBP and chemokine, binding interface, and the role of
electrostatic complementarity in complex formation. The SE-
CRET domain utilizes its b-sheet I to interact with CX3CL1,
whereas vCCI utilizes its b-sheet II to interact with CCL4 upon
complex formation. The vCCI/CCL4 binding interface, burying a
total surface of ,990 A ˚ 2, can be divided into two patches. The
patch 1 between the N-loop of CCL4 and vCCI is primarily
composed of hydrophobic interactions around CCL4 residue F13
and salt-bridge interactions around CCL4 residue R18 (Figure S6
in Text S1A) [36]. These two positions are conserved in CC
chemokines and mutation of them dramatically decreased the
binding of CC chemokines by vCCI [37,38]. The patch 2 is
between the basic 40s loop of CCL4 and the extended and acidic
2–3 loop of vCCI (Figure S6 in Text S1A), and the electrostatic
complementarity is expected to drive the interactions between
Table 1. Crystallographic statistics.
Native SECRET Br-soaked SECRET SECRET/CX3CL1
Data collection
Beamline SSRF BL-17U SSRF BL-17U SSRF BL-17U
Wavelength 0.9793 0.9195 0.9795
Space group C2221 C2221 P3221
Cell dimensions
a, b, c (A ˚) 72.42, 73.44, 112.41 72.42, 73.42, 112.55 71.33, 71.33, 93.14
a, b, c (u) 90, 90, 90 90, 90, 90 90, 90, 120
Resolution (A ˚) 50–1.57 (1.61–1.57) 50.0–1.46 (1.49–1.46) 50.0–2.60 (2.69–2.60)
Rmerge (%) 7.8 (39.8) 5.7 (24.9) 10.0 (86.7)
I/sI 17.9 (2.4) 58 (9.7) 17.4 (1.8)
Completeness (%) 98.3 (87.6) 100 (100) 99.9 (99.3)
Redundancy 3.9 (3.2) 9.5 (9.0) 7.1 (6.4)
Refinement
Resolution (A ˚) 30.7–1.57 30.0–2.60
No. Reflections 39277 8262
Rwork/Rfree (%) 16.4/19.9 19.6/25.0
No. atoms
Protein 2493 1743
water 466 28
B-factors (A ˚2)
Protein 20.4 75.6
water 32.7 61.7
R.m.s. deviations
Bond lengths (A ˚) 0.006 0.010
Bond angles (u) 1.130 1.282
Ramachandran plot
Most favored 88.4 81.1
Allowed 10.9 16.5
Generally allowed 0.3 1.9
Disallowed 0.3 0.5
doi:10.1371/journal.ppat.1002162.t001
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of CCL4 were mutated to Ala in the vCCI/CCL4 complex
structure (Figure S6 in Text S1A) [36]. The smaller SECRET/
CX3CL1 interface (,530 A ˚ 2) is composed one contact patch with
a small hydrophobic core and surrounding hydrophilic interac-
tions as described above (Figure 4B). The region from C8 to M15
of the N-loop is far away from the SECRET domain, so the
SECRET domain does not utilize critical hydrophobic interac-
tions observed in the vCCI/CCL4 contact patch 1 to bind
CX3CL1. The corresponding position of R18 in CCL4 is K18 in
CX3CL1, which forms salt-bridge interaction with D316 of the
SECRET domain to surround the hydrophobic core (Figure 4D)
and is also important for their binding (Table 2). Structural
superimposition based on bound chemokines revealed that the
Figure 2. Structural comparison of the SECRET domain with vCCI and A41. (A) The conformational change of the 7–9 loop colored with
purple. (B) The conformational change of the 2–3 loop colored with purple. (C) The conformational change of the 6–7 loop colored with purple.
doi:10.1371/journal.ppat.1002162.g002
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patch 2 in the vCCI/CCL4 interface (Figure S6 in Text S1A).
Although obvious electrostatic complementarity is observed in
both the SECRET/CX3CL1 interface (Figure 4C) and the
contact patch 2 in the vCCI/CCL4 interface (Figure S6 in Text
S1A), the electrostatic interactions around the basic 40s loop of
bound chemokine play a different role in the formation of these
two complexes. Residues R44 and R47 of CX3CL1 are critical
because mutations at these positions caused respective ,24-fold
and ,54-fold drop in the binding of CX3CL1 by the SECRET
domain (Table 2). In contrast, a triple mutant of CCL4 (K45A/
R46A/K48A) had nearly the same binding affinity as wild type
CCL4, as determined by ELISA method [36]. In CCL2, the
K49A mutation even increased its binding affinity with vCCI
[37,38]. Therefore, the contact patch 2 around the 40s loop of
chemokines might contribute to chemokine binding of vCCI by
providing an electronegative platform to recruit different CC
chemokines, while the conserved hydrophobic and hydrophilic
interactions around the N-loop of CC chemokines in the contact
patch 1 determine the high affinity binding of CC chemokines by
vCCI. The contact patch around the basic 40s loop of CX3CL1
has dual roles, not only helping the recruitment of a subset of
chemokines from different classes by the SECRET domain, but
also providing critical interactions for the complex formation.
Parasites, such as blood-sucking ticks and Schistosoma mansoni,
also secrete CKBPs with anti-inflammatory activities [39,40,41].
Evasin, a new family of CKBPs encoded by ticks, comprises four
members that may help inhibit chemokine-mediated host innate
Figure 3. Electrostatic potential surfaces. (A) vCCI. (B) A41. (C) SECRET domain.
doi:10.1371/journal.ppat.1002162.g003
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Evasin-1 is very restrictive by only binding CCL3, CCL4 and
CCL18 [40]. The Evasin-1 adopts a novel fold and it interacts
with bound CCL3 by primarily contacting its N-loop region, as
revealed in the Evasin-1/CCL3 complex structure (Figure S6 in
Text S1B) [42]. Structural superimposition based on bound
chemokines revealed that the SECRET-binding and Evasin-1-
binding epitopes on chemokines are distinct with little overlap
(Figure S6 in Text S1B). Therefore, the SECRET domain and
Evasin-1 are different in the chemokine-binding manner.
Figure 4. Crystal structure of the SECRET/CX3CL1 complex. (A) Ribbon diagram of the SECRET domain (green) in complex with CX3CL1
(purple). (B) Residues at the binding interface. Residues with solvent accessible surface decrease of above 80%, 60–80%, 40–60%, and below 40%
upon complex formation are colored in brown, cyan, yellow, and green, respectively. (C) Electrostatic complementarity at the binding interface. The
SECRET domain and CX3CL1 are in the same orientation as in panel B. D) Detailed view of the interactions at the binding interface. Hydrophilic
interactions around basic residues K18, R44, and R47 of CX3CL1 are shown as dashed lines.
doi:10.1371/journal.ppat.1002162.g004
Table 2. Binding measurements of the SECRET domain with CX3CL1 wild type and its mutants by surface plasmon resonance
(SPR) analysis.
Fit model First measurement Second measurement KD (mM)
KD (mM) kon (M
21s
21)k off (s
21)K D (mM) kon (M
21s
21)k off (s
21) Mean SE of mean
WT Steady state 0.421 0.937 0.68 0.26
K18A Kinetics 11.5 0.45e3 5.18e-3 10.3 1e3 10.3e-3 10.9 0.6
I19A Kinetics 1.28 5.38e3 6.89e-3 0.641 9.02e3 5.78e-3 0.96 0.32
L23A Steady state 3.36 5.62 4.49 1.13
R44A Steady state 15.7 16.6 16.15 0.45
R47A Steady state 34.5 38.4 36.45 1.95
F49A Steady state 3.75 4.64 4.20 0.45
doi:10.1371/journal.ppat.1002162.t002
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dimer in solution, in contrast to other monomeric poxviral
CKBPs. The two M3 monomers are arranged in a ‘‘head-to-tail’’
manner, each monomer consisting of the N-terminal domain
(NTD) and C-terminal domain (CTD) (Figure S6 in Text S1C)
[21]. Unlike the SECRET/CX3CL1 complex in 1:1 stoichiom-
etry, the M3 dimer utilizes the NTD of one monomer and the
CTD of the other monomer to form two clefts to bind two
chemokines, forming a complex in 2:2 stoichiometry (Figure S6 in
Text S1C) [21,23]. The SECRET domain and the NTD of M3
have positional overlap around the 40s loop of bound chemokine
(Figure S6 in Text S1C). The Evasin-1 and the CTD of M3 have
positional overlap around the N-loop of bound chemokine (Figure
S6 in Text S1C). Therefore, M3 seems to combine different
chemokine-binding manners of the SECRET domain and Evasin-
1 by utilizing both NTD and CTD in the binding of chemokines.
The SECRET domain interferes with the interaction of
CX3CL1 with both GAG and cellular receptor
We conducted a SPR experiment as reported for other viral
CKBPs (VACV A41 and ECTV E163) to test if the SECRET
domain can interfere with the interaction of CX3CL1 with GAG
[17,18]. The CX3CL1 was pre-incubated with various amount of
heparin (sodium salt, molecular weight ,15 KDa), and then
injected over the SECRET-coupled sensor chip. Heparin
decreased the binding of CX3CL1 by the SECRET domain in
a dose-dependent manner (Figure 5), indicating the overlap of
SECRET-binding and GAG-binding sites on CX3CL1. In our
experiment, the concentration of heparin required for the
inhibition was much higher than that used to achieve the
disruption of chemokine binding by A41 and E163 [17,18]. This
may be caused by the reported low binding affinity between
CX3CL1 and heparin [23].
It has also been shown that the SECRET domain can inhibit
the CCL25-mediated Molt4 cell migration, indicating its ability to
interfere with binding of CCL25 with its cellular receptors [18,30].
We also checked the ability of recombinant CX3CL1 in inducing
migration of RAW264.7 cell as reported [43], as well as the ability
of the SECRET domain to inhibit cell migration. CX3CL1
induced the migration of RAW264.7 cells in a dose-dependent
manner, indicated by the decrease of cells remaining in the top
well with the increase of CX3CL1 concentration in the bottom
well (Figure 6A). Chemokinesis, defined as a random movement of
cells in a zero gradient (equal amounts of starting chemoattractant
in both top and bottom wells), was very low (Figure 6A). Pre-
incubation of CX3CL1 with excessive SECRET domain signif-
icantly reduced the CX3CL1-mediated cell migration (Figure 6B).
We also expressed and purified the SECRET domain with a triple
mutation D167A/E169A/D316A by replacing its acidic residues
involved in the critical salt-bridge interactions at the SECRET/
CX3CL1 interface. Gel-filtration and circular dichroism (CD)
spectroscopy profiles indicate that this mutant was properly folded
and purified as the wild type protein (Figure S7 in Text S1). This
SECRET domain mutant lost most of the inhibitory ability
(Figure 6B). These results together suggest that the SECRET
domain is able to interfere with the binding of CX3CL1 with its
receptors on cell surface.
The SECRET domain binds different chemokines similarly
The measured binding affinity (,0.68 mM) between the
SECRET domain and CX3CL1 in our experiment is lower than
previous reported binding affinities between the SECRET domain
and CCL28, CCL25, CXCL12, CXCL13, CXCL14, XCL1, and
CCL20 that are in nM range [30]. This raises the question if the
SECRET domain binds other chemokines in a manner similar to
that observed in the SECRET/CX3CL1 complex structure. To
help answer this question, we examined the binding ability of the
SECRET domain D167A/E169A/D316A mutant. Besides
CX3CL1, CCL28, CCL25 and CXCL12 were chosen because
they were the previously reported top three in the binding with the
CrmB and CrmD [30]. The SPR analysis showed that the triple
mutations in the SECRET domain not only disrupted its binding
with CX3CL1, but also with CCL28, CCL25, and CXCL12 to
undetectable level (Figure 7), indicating that the SECRET domain
binds different chemokines in a similar manner.
Discussion
GAG binding plays important roles in the in vivo function of
chemokines, including helping immobilize chemokines to form a
concentration gradient along which cells can migrate directionally,
protecting chemokines from proteolysis, and inducing chemokine
oligomerization [44,45]. It has been suggested that four distinct
basic clusters on the surface of chemokines are major GAG-
binding sites for different chemokines [8]. These four clusters all
involve residues from the basic 40 loops. Residues on the
chemokines important for GAG binding have also been
characterized by mutagenesis studies for several chemokines
including CCL2, CCL3, CCL4, CCL5, CXCL8, CXCL12, and
XCL1 [6,7]. Basic residues from the 40s loop participate in the
binding of GAG by all studied chemokines except CXCL8 [6,7].
The respective structures of CCL5 and CXCL12 with heparin-
derived disaccharides also confirmed that the BBXB motif (where
B and X stand for basic and neutral/hydrophobic amino acid) of
the 40s loop participates in GAG binding [46,47]. The inhibition
of chemokine-GAG interaction by M3 is also attributed to its
interaction with the basic 40s loop of bound chemokine by the
NTD [23]. These previous results all suggest that the basic 40s
loop of chemokines is generally involved in the GAG-binding. In
the SECRET/CX3CL1 complex structure, the basic residues R44
and R47 from the 40s loop of CX3CL1 have direct interaction
with the SECRET domain. We have also shown that heparin can
interfere with the binding of CX3CL1 by the SECRET domain in
a dose-dependent manner (Figure 5), similar to the interference of
heparin in the chemokine binding of A41 and E163 [17,18]. These
data together indicate that the SECRET domain is able to block
the chemokine-GAG interaction.
The inhibitory ability of the SECRET domain for CCL25 and
CX3CL1 induced cell migration indicates that it is able to
interfere with the chemokine-receptor interaction. It is generally
accepted that the N-termini of chemokines is the key signaling
domain, and other residues in the N-loop and core domain can
also be critical for the binding with chemokine receptors. For
example, the residues 12–17 in the N-loop of CXCL12 were
shown to be important for receptor binding [47,48]. The N-loop
region (residues 13–20) of CC chemokines promotes tight binding
to the chemokine receptors [49,50]. The vCCI and M3 interfere
with the chemokine-receptor interaction by completely blocking
the accessibility of the N-loop region of bound chemokine, as
revealed in the complex structure of vCCI with CCL4, and M3
with CCL2 and XCL1 [21,23,36]. The N-loop of CX3CL1 is not
completely blocked by the SECRET domain. The S13 position at
the N-terminal part of the N-loop critical for the binding of
chemokines by vCCI and M3 is accessible in the SECRET/
CX3CL1 complex, but residues T16, S17, K18, and I19 at the C-
terminal part of the N-loop region have interaction with the
SECRET domain. It suggests that although the SECRET domain
does not directly block the most important receptor binding site on
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PLoS Pathogens | www.plospathogens.org 8 July 2011 | Volume 7 | Issue 7 | e1002162Figure 5. The SPR analysis of SECRET-CX3CL1 interaction in the presence of heparin. (A) Sensorgrams of passing CX3CL1 pre-incubated
with an increased concentration of heparin (sodium salt, molecular weight ,15 KD) (0, 0.125, 0.25, 0.5, 1, 2, and 4 mg/ml) through the CM5 chip
surface immobilized with the SECRET domain. The binding of CX3CL1 without heparin pre-incubation (0 mg/ml) by the SECRET domain was checked
again (response curve in black) after finishing all other measurements to make sure that the decrease of response was not due to the change of chip
surface. (B) Heparin interferes with the binding of CX3CL1 by the SECRET domain in a dose-dependent manner.
doi:10.1371/journal.ppat.1002162.g005
Figure 6. CX3CL1-induced migration of RAW 264.7 cells. (A) The number of cells remaining in the top well counted by FACS after a 4-h
chemotaxis assay are indicated with CX3CL1 in concentrations of 0.01, 0.1, 0.5, and 1.0 mM in the bottom well, as well as the same concentration
1.0 mM in both top and bottom wells. (B) The number of cells remaining in the top well counted by FACS after a 4-h chemotaxis assay are indicated
with CX3CL1, CX3CL1 pre-incubated with the SECRET domain in different molar ratio (1:1, 1:5, and 1:10), and CX3CL1 pre-incubated with the SECRET
domain triple mutant D167A/E169A/D316A in a 1:10 molar ratio. The D167A/E169A/D316A mutant is referred as 3A mutant in the figure.
doi:10.1371/journal.ppat.1002162.g006
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the N-loop), its binding is still close to the receptor binding site and
bring steric hindrance to prevent efficient interaction with the
receptor, which would provide a structural basis for the ability of
the SECRET domain to inhibit CX3CL1 and CCL25 induced
cell migration.
The previous study reporting the discovery of the SECRET
domain has shown that it is capable of binding CCL28, CCL25,
CCL20, CXCL12, CXCL13, CXCL14 and XCL1 that are from
the CC, CXC, and C classes. We have shown here that it is also
able to bind CX3CL1, the only member in the CX3C class. The
ability of previous reported M3 to bind a subset of chemokines
from all four classes is attributed to its structural plasticity (i.e. the
structural rearrangement of NTD and CTD) and the use of
flexible loops as primary contact sites for chemokines from
different classes [21,23]. In comparison, the SECRET domain has
a much smaller solvent exposed surface on the relatively rigid b-
sheet I to contact chemokines from four different classes,
demanding the focus on more common amino acid motifs on
chemokines. In the SECRET/CX3CL1 complex structure,
critical residues R44 and R47 for the complex formation are
from the 40s loop, which can be regarded as hot-spot residues for
the interaction. The presence of basic residues in the 40s loop is
also found in other chemokines bound by the SECRET domain.
The electrostatic complementary between the basic 40s loop of
bound chemokine and acidic b-sheet I surface of the SECRET
domain would enable the SECRET domain to bind different
chemokines, allowing some extent of conformational variation in
the 40s loop. There are two questions need to be answered in the
future study: (1) Why is the SECRET domain not able to bind
other chemokines also with the presence of basic residues in the
40s loop? (2) Why is the binding affinity of the SECRET domain
with CX3CL1 lower than with previous reported chemokines?
Sequence alignments of CX3CL1, CCL28, CCL25, CCL20,
CXCL12, CXCL13, CXCL14, and XCL1 did not reveal obvious
conserved motifs in the 40s loop (Figure S8A in Text S1) that are
absent in chemokines unable to bind the SECRET domain.
Previous NMR studies indicated that the flexibility of the N-loop is
greater than the flexibility of other regions of chemokines
(excluding the N- and C-termini) [51]. Only the C-terminal part
of the N-loop of CX3CL1 is involved in the interaction with the
SECRET domain. Due to the flexibility of the N-loop, it may
more extensively participate in the interactions of CCL28,
CCL25, CCL20, CXCL12, CXCL13, CXCL14 and XCL1 with
the SECRET domain, and the chemokine selectivity of the
SECRET domain may also reside in the flexible N-loop region.
Figure 7. Sensograms of passing the SECRET domain wild type (green) and D167A/E169A/D316A mutant (red) through the CM5
chip surface immobilized with chemokines CX3CL1, CCL28, CCL25, and CXCL12, respectively. The D167A/E169A/D316A mutant is
referred as 3A mutant in the figure.
doi:10.1371/journal.ppat.1002162.g007
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structural studies of the SECRET domain with chemokines from
C, CC, and CXC classes.
Besides CrmB and CrmD, genome analysis also identified other
genes encoding SECRET domain containing proteins (SCPs) [30].
The reported SCPs that bind to the same set of chemokines as
CrmB and CrmD are CPXV V218 (SCP-1), ECTV E12 (SCP-2),
and ECTV E184 (SCP-3) [30]. The primary sequence of the
SECRET domain is much more conserved in CrmB and CrmD
than in SCP-1, SCP-2, and SCP-3 (Figure S8B and S8C in Text
S1). Among the fifteen residues in the SECRET domain of ECTV
CrmD that have contacts with CX3CL1 in complex formation
(Figure 4B and Figure S8B in Text S1), seven of them are strictly
conserved in CrmB from VARV and CPXV and CrmD from
ECTV and CPXV, including important charged residues D167
and E169 (Figure S8B in Text S1). Another important charged
residue D316 is conserved in CrmD, but is replaced by arginine in
CPXV CrmB and serine in VARV CrmB (Figure S8B in Text S1).
Residues interacting with CX3CL1 in the SECRET domain are
not highly conserved in SCP-1, SCP-2, and SCP-3 (Figure S8C in
Text S1). This indicates that the binding of chemokines by these
SCP proteins may be different from the binding by the SECRET
domain.
Methods
Purification of the SECRET domain
The gene encoding the SECRET domain of CrmD (residues
1622320) was cloned into EcoRI and NcoI restriction sites of the
pProEx HTb expression vector. The resulting plasmid was
transformed into E. coli BL21 (DE3) competent cells. Three liters
of LB media containing 100 mg/ml ampicillin were inoculated and
grown to A600 of 0.8 and then induced with 0.6 mM IPTG.
Induced cultures were grown for an additional 4 h at 37uC and
harvested by centrifugation for 10 min at 5,000 rpm. Cells were
resuspended in 25 mM Tris-HCl, 50 mM NaCl, pH 8.0, lysed
with sonication and centrifuged for 50 min at 15,000 rpm. The
SECRET domain was found exclusively in the inclusion bodies.
The inclusion bodies were washed three times in wash buffer A
(25 mM Tris-HCl, 50 mM NaCl, 5 mM EDTA, 5% Triton X-
100, pH 8.0) and once in wash buffer B (25 mM Tris?HCl,
50 mM NaCl, 5 mM EDTA, pH 8.0). Washed inclusion bodies
were solubilized in 8 M Urea, 50mM DTT and diluted into a
refolding buffer (25 mM Tris-HCl, 50 mM NaCl, 0.2 mM
oxidized glutathione, 2 mM reduced glutathione, pH 8.0) and
stirred at 4uC overnight, and then dialyzed against 25 mM Tris-
HCl, 50 mM NaCl, pH 8.0. The refolded SECRET domain was
bound to HisTrap column, then washed with 25mM Tris-HCl,
50 mM NaCl, 20 mM Imidazole, pH 8.0 and eluted with 25 mM
Tris-HCl, 50 mM NaCl, 500 mM imidazole, pH 8.0. Fractions
containing the SECRET domain were examined by SDS-PAGE
gel, pooled and further purified with size exclusion column. The
SECRET mutant (D167A/E169A/D316A) was expressed and
purified by the same method as wild type SECRET domain. To
check the SECRET domain is a dimer or monomer in solution,
molecular weight standards and the SECRET domain (0.5 ml,
1.5 mg/ml) were loaded onto Superdex 75 size exclusion column
with a flow rate of 0.5 ml/min.
Purification of CX3CL1 and the SECRET/CX3CL1 complex
The gene encoding the chemokine domain of human CX3CL1
(residues 1–76) was cloned into the EcoRI and NcoI restriction
sites of the pProEX HTb expression vector. The resulting plasmid
was transformed into E. coli BL21 (DE3) competent cells. Three
liters LB media containing 100 mg/ml ampicillin were inoculated
and grown to A600 of 0.8 and then induced with 1.0 mM IPTG.
Induced cultures were grown for an additional 4 h at 37uC and
harvested by centrifugation for 10 min at 5,000 rpm. Cells were
resuspended in PBS buffer (pH 7.2), lysed by sonication and
centrifuged for 50 min at 15,000 rpm. CX3CL1 was found
exclusively in the inclusion bodies. The inclusion bodies were
washed three times in wash buffer A (25 mM Tris?HCl, 50 mM
NaCl, 5 mM EDTA, 5% Triton X-100, pH 8.0) and once in wash
buffer B (25 mM Tris?HCl, 50 mM NaCl, 5 mM EDTA, pH 8.0).
Washed inclusion bodies were solubilized in 8 M Urea, 50 mM
DTT and diluted into a refolding buffer (PBS, 0.2 mM oxidized
glutathione, 2 mM reduced glutathione, pH 7.2) and stirred at
4uC overnight. Precipitated material was removed by filtration.
Refolded protein was bound to a HisTrap column and washed
with PBS buffer, 20 mM Imidazole then eluted with PBS buffer,
500 mM Imidazole. Fractions containing CX3CL1 were exam-
ined by SDS-PAGE gel, pooled and further purified with size
exclusion column. All CX3CL1 mutants were expressed and
purified by the same method as wild type CX3CL1. Purified
SECRET domain and wild type CX3CL1 were mixed, left on ice
for 1 h, and subjected to size exclusion column purification to
obtain the SECRET/CX3CL1 complex.
Crystallization and data collection
The SECRET domain and the SECRET/CX3CL1 complex
were concentrated by ultrafiltration to ,15 mg/ml. Crystals of the
SECRET domain were grown from a mother liquor of 0.4 M
Magnesium formate dehydrate, 0.1 M Bis-Tris propane, pH 7.0
with hanging-drop vapor diffusion method at room temperature.
Crystals of the SECRET/CX3CL1 complex were grown from
0.2 M Lithium sulfate monohydrate, 0.1 M Tris?HC, pH 8.5,
20% PEG4000 with hanging-drop vapor diffusion method at
room temperature.
Crystals of the SECRET domain were cryoprotected in well
solution plus 20% (v/v) glycerol and cooled to 100 K before data
collection. For the SAD data collection, crystals were soaked in
well solution with 0.2 M NaBr for 30 s before data collection.
Crystals of the SECRET/CX3CL1 complex were cryoprotected
in well solution plus 20% (v/v) glycerol and cooled to 100 K
before data collection. All diffraction data were collected at
Shanghai Synchrotron Research Facility (SSRF) beamline BL17U.
All data were indexed and integrated and scaled with program
HKL2000 [52].
Structure determination and refinement
The structure of the SECRET domain was solved using the Br-
SAD method. The positions of the Br were determined using the
program SHELXD [53] and initial phases computed with the
program SHELXE [54] as part of the HKL2MAP package [55].
Density modification was conducted using DM from the CCP4
suite [56]. The resulting electron density map was of excellent
quality, allowing an automatic chain trance to be performed with
the program Arp/wARP [57]. The following model adjustment
and structural refinement were conducted using the program
COOT [58] and PHENIX [59], respectively. For the final model,
the Rwork is 16.4%, and the Rfree is 19.9%. The structure of the
SECRET/CX3CL1 complex was solved using the molecular
replacement method with the SECRET domain and the CX3CL1
structures as search models in the program PHASER [60].
Iterative refinement with the program PHENIX [59] and model
building with the program COOT [58] were conducted, yielding a
final Rwork of 19.6% and Rfree of 25.0%. All structural figures were
made by using PYMOL (http://www.pymol.org).
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The binding affinity between the SECRET domain and
CX3CL1 was determined by surface plasmon resonance (SPR)
using BIAcore 3000 at 25uC. The SECRET domain was
immobilized to about 350 Response Unit (RU) on a research-
grade CM5 sensor chip in 10 mM sodium acetate, pH 4.1 by
standard amine coupling method. The flow cell 1 was left blank as
a reference. To measure binding affinity of CX3CL1 wild type
and mutants by the SECRET domain, CX3CL1 in 10 mM
HEPES, pH 7.2, 150 mM NaCl, and 0.005% Tween-20 were
injected over the flow cells at different concentrations at a flow rate
of 30 ml min
21. The binary complexes were allowed to associate
for 90 s and dissociate for 90 s. The surfaces were regenerated
with 5 mM NaOH between each cycle if needed. Data were
analyzed with BIAcore 3000 evaluation software BIAevaluation
4.1.
To investigate the interference of heparin in the binding of
CX3CL1 by the SECRET domain, 1 mM wild type CX3CL1 was
pre-incubated with increasing concentrations (0.125, 0.25, 0.5,
1.0, 2.0, 4.0 mg/ml) of heparin sodium salt (MW ,15,000 Da,
Sigma-Aldrich) at 4uC for 1 h. SPR analysis was performed as
above.
To compare the binding ability of the SECRET domain wild
type and mutant by chemokines, CX3CL1 purified by ourselves,
CCL28, CCL25, and CXCL12 purchased from PeproTech were
immobilized on the CM5 chip to ,200 RU. SPR analysis was
performed as above.
Chemotaxis assay
RAW 264.7 cells were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS at 37uCi nC O 2
incubator. Serum-starved RAW 264.7 cells with a total number of
1610
7 were suspended in PBS buffer with 1 mM CellTracker
Green CMFDA (Invitrogen) and incubated at 37uC for 5 minutes.
The labeled cells were collected, washed three times with PBS
buffer to remove the excessive CMFDA, and then suspended in
RPMI 1640 medium for cell migration assays.
Cell chemotaxis assay was performed using 8 mm2pore Cell
Culture Inserts (Millipore). The inserts were placed into 24-well
plates containing RPMI1640 in the presence or the absence of
CX3CL1 and SECRET domain. We seeded 8610
4 CMFDA-
labeled cells in each transwell insert and incubated at 37uC for
4 hours. Cell migration was quantified by counting the number of
cells that remaining in the upper transwell by FACS.
Accession numbers
The coordinates of the SECRET domain and SECRET/
CX3CL1 structures have been deposited into the Protein Data
Bank with accession numbers 3ON9 and 3ONA, respectively.
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